| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenue for the current quarter increased by 5.2% year‑on‑year to SAR 481.4 million, supported by sustained demand, disciplined commercial execution, and volume‑led growth across key markets. Performance was further supported by diversified geographic exposure, with growth recorded across Saudi Arabia, the Gulf region, and North Africa. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit increased by 7.1% year‑on‑year to SAR 168.2 million, growing faster than revenue due to improved operating leverage, effective cost discipline, and favorable product and customer mix. This resulted in a modest expansion in net profit margin to 34.9% during the quarter. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Revenue for the current quarter has increased by 58.1% compared to 4Q 2025, primarily driven by higher demand across key markets and therapeutic areas, as well as the impact of seasonality, with the fourth quarter typically reflecting lower sales compared to other periods of the year. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | The Company’s net profit increased by 147.1% during the current quarter compared to the previous quarter, driven by higher sales, improved gross margins, and more efficient absorption of operating expenses. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | The interim condensed consolidated financial statements of the Group for the three-month period ended 31 March 2025 were reviewed by another auditor who expressed an unmodified review conclusion on those financial statements on 1 May 2025 (corresponding to 3 Dhul Qadah 1446H). |
| Reclassification of Comparison Items | None |
| Additional Information | As at 31 March 2026, cash balance was SAR 206.1 million, which represented a decrease of 42.4% compared to the balance at 31 December 2025, primarily due to dividends paid in the first quarter. This demonstrates the Company's ability to sustain the strength of its core operations and generate liquidity whilst returning value to shareholders through dividend distributions. Please refer to the attached Earnings Release for more information on the 1Q 2026 results. |
| Attached Documents | Attached Documents |
